• 1
    Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004; 116: 337-350.
  • 2
    Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005; 56: 45-62.
  • 3
    Esteghamati A, Khalilzadeh O, Anvari M et al. Metabolic syndrome and insulin resistance significantly correlate with body mass index. Arch Med Res 2008; 39: 803-808.
  • 4
    Gomez-Ambrosi J, Silva C, Galofre JC, et al. Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes (Lond) 2012; 36: 286-294.
  • 5
    Dervaux N, Wubuli M, Megnien JL, Chironi G, Simon A. Comparative associations of adiposity measures with cardiometabolic risk burden in asymptomatic subjects. Atherosclerosis 2008; 201: 413-417.
  • 6
    Gómez-Ambrosi J, Silva C, Galofré JC et al. Body adiposity and type 2 diabetes: increased risk with a high body fat percentage even having a normal BMI. Obesity (Silver Spring) 2011; 19: 1439-1444.
  • 7
    Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
  • 8
    Shaw DI, Tierney AC, McCarthy S, et al. LIPGENE food-exchange model for alteration of dietary fat quantity and quality in free-living participants from eight European countries. Br J Nutr 2009: 101: 750-759.
  • 9
    Tierney AC, McMonagle J, Shaw DI et al. Effects of dietary fat modification on insulin sensitivity and on other risk factors of the metabolic syndrome-LIPGENE: a European randomized dietary intervention study. Int J Obes (Lond) 2011; 35: 800-809.
  • 10
    Matthie J. In: technologies X, (ed). Hydra ECF/ICF Bio-Impedance Analyzer (Mode 4200) Operational Manual Revision 1.01. Xitron Technologies: San Diego, CA, 1997, pp 44-48.
  • 11
    Bosy-Westphal A, Geisler C, Onur S et al. Value of body fat mass vs anthropometric obesity indices in the assessment of metabolic risk factors. Int J Obes (Lond) 2006; 30: 475-483.
  • 12
    Deurenberg P, Andreoli A, Borg P et al. The validity of predicted body fat percentage from body mass index and from impedance in samples of five European populations. Eur J Clin Nutr 2001; 55: 973-979.
  • 13
    Okorodudu DO, Jumean MF, Montori VM et al. Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis. Int J Obes (Lond) 2010; 34: 791-799.
  • 14
    Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
  • 15
    Perseghin G, Caumo A, Caloni M, Testolin G, Luzi L. Incorporation of the fasting plasma FFA concentration into QUICKI improves its association with insulin sensitivity in nonobese individuals. J Clin Endocrinol Metab 2001; 86: 4776-4781.
  • 16
    Wildman RP, Muntner P, Reynolds K et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med 2008; 168: 1617-1624.
  • 17
    De Lorenzo A, Martinoli R, Vaia F, Di Renzo L. Normal weight obese (NWO) women: an evaluation of a candidate new syndrome. Nutr Metab Cardiovasc Dis 2006; 16: 513-523.
  • 18
    Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
  • 19
    Karelis AD, Messier V, Brochu M, Rabasa-Lhoret R. Metabolically healthy but obese women: effect of an energy-restricted diet. Diabetologia 2008; 51: 1752-1754.
  • 20
    Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
  • 21
    Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004; 53: 693-700.
  • 22
    Mosca L. C-reactive protein-to screen or not to screen? N Engl J Med 2002; 347: 1615-1617.
  • 23
    Spranger J, Kroke A, Möhlig M et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52: 812-817.
  • 24
    De Lorenzo A, Del Gobbo V, Premrov MG et al. Normal-weight obese syndrome: early inflammation? Am J Clin Nutr 2007; 85: 40-45.
  • 25
    Wannamethee SG, Lowe GD, Rumley A et al. Adipokines and risk of type 2 diabetes in older men. Diabetes Care 2007; 30: 1200-1205.
  • 26
    Söderberg S, Ahrén B, Jansson JH et al. Leptin is associated with increased risk of myocardial infarction. J Intern Med 1999; 246: 409-418.
  • 27
    Wallace AM, McMahon AD, Packard CJ et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104: 3052-3056.
  • 28
    Inoue M, Maehata E, Yano M, Taniyama M, Suzuki S. Correlation between the adiponectin-leptin ratio and parameters of insulin resistance in patients with type 2 diabetes. Metab Clin Exp 2005; 54: 281-286.
  • 29
    Inoue M, Yano M, Yamakado M, Maehata E, Suzuki S. Relationship between the adiponectin-leptin ratio and parameters of insulin resistance in subjects without hyperglycemia. Metab Clin Exp 2006; 55: 1248-1254.
  • 30
    Bolanowski M, Nilsson BE. Assessment of human body composition using dual-energy x-ray absorptiometry and bioelectrical impedance analysis. Med Sci Monit 2001; 7: 1029-1033.
  • 31
    Barbarroja N, López-Pedrera R, Mayas MD et al. The obese healthy paradox: is inflammation the answer? Biochem J 2010; 430: 141-149.
  • 32
    Koster A, Stenholm S, Alley DE et al. Body fat distribution and inflammation among obese older adults with and without metabolic syndrome. Obesity (Silver Spring) 2010; 18: 2354-2361.
  • 33
    Snijder MB, Dekker JM, Visser M et al. Associations of hip and thigh circumferences independent of waist circumference with the incidence of type 2 diabetes: the Hoorn Study. Am J Clin Nutr 2003; 77: 1192-1197.
  • 34
    Snijder MB, Dekker JM, Visser M et al. Trunk fat and leg fat have independent and opposite associations with fasting and postload glucose levels: the Hoorn study. Diabetes Care 2004; 27: 372-377.
  • 35
    Beasley LE, Koster A, Newman AB et al. Inflammation and race and gender differences in computerized tomography-measured adipose depots. Obesity (Silver Spring) 2009; 17: 1062-1069.
  • 36
    Kennedy A, Martinez K, Chuang CC, LaPoint K, McIntosh M. Saturated fatty acid-mediated inflammation and insulin resistance in adipose tissue: mechanisms of action and implications. J Nutr 2009; 139: 1-4.
  • 37
    Vessby B. Dietary fat, fatty acid composition in plasma and the metabolic syndrome. Curr Opin Lipidol 2003; 14: 15-19.
  • 38
    Lopez-Garcia E, Schulze MB, Manson JE et al. Consumption of (n-3) fatty acids is related to plasma biomarkers of inflammation and endothelial activation in women. J Nutr 2004; 134: 1806-1811.
  • 39
    Madsen T, Skou HA, Hansen VE et al. C-reactive protein, dietary n-3 fatty acids, and the extent of coronary artery disease. Am J Cardiol 2001; 88: 1139-1142.
  • 40
    Paniagua JA, Pérez-Martinez P, Gjelstad IM et al. A low-fat high-carbohydrate diet supplemented with long-chain n-3 PUFA reduces the risk of the metabolic syndrome. Atherosclerosis 2011; 218: 443-450.